Frontotemporal dementia (FTD) is a devastating neurodegenerative disease that commonly afflicts people in middle age, when they are in the prime of life.
1 The early diagnosis of FTD is critical for developing management strategies and interventions for these patients. Most individuals who develop FTD manifest with new-onset behavioral symptoms,
2-6 and, in the absence of a biomarker, the clinical diagnosis depends on recognizing all the core, or necessary, neuropsychiatric features of FTD.
1,2